Compare PLG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLG | IMUX |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | Canada | United States |
| Employees | N/A | 66 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.3M | 209.2M |
| IPO Year | 2002 | 2013 |
| Metric | PLG | IMUX |
|---|---|---|
| Price | $1.44 | $16.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 900.4K | 133.5K |
| Earning Date | 04-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $0.51 |
| 52 Week High | $4.04 | $16.86 |
| Indicator | PLG | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 65.03 |
| Support Level | $1.24 | $0.75 |
| Resistance Level | $1.61 | N/A |
| Average True Range (ATR) | 0.08 | 1.08 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 52.05 | 88.54 |
Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.